He is head of the section of Cellular Neuropharmacology and has a long-standing track record for experimental research into identification and characterization of novel targets for the development of disease modifying treatments for neurodegenerative disorders, in particular Parkinson’s- and Alzheimer’s disease and Multiple Sclerosis. Wthin this context he has studied transglutaminases as a potential treatment target since 2005, recently extending his interest into developing PET ligands for the in vivo detection of transglutaminase activity under pathological conditions and the monitoring of the effects of transglutaminase modifying drugs.